Document:

Exhibit 10.19

                                Service Agreement
                             Letter of Understanding

                                    6/12/2001

This  letter  of  understanding,  agreed to on June 13, 2001 by both parties, is
intended  to  outline  the  operational  and  financial arrangement between ARUP
Laboratories  ("ARUP")  of  Salt Lake City, Utah and Biomedical Diagnostics, LLC
("BMD") of Ann Arbor, Michigan in regards to sale of the Mammastatin Serum Assay
("MSA").  This  letter outlines terms for the sale of products and services that
BMD  will  provide  to  ARUP.

BMD  represents  that  it  is  a  Michigan  Company  that  has  obtained  CLIA
Certification  as  a  clinical testing laboratory through the State of Michigan,
and  has initiated registration with New York State Department of Health. BMD is
also  authorized to market the MSA, which is derived technology developed at the
University  of  Michigan  and  licensed  to  Biotherapies,  Incorporated.

ARUP  is  a  clinical  laboratory,  wholly-owned by the University of Utah, that
desires  to  offer  the  MSA  test  to  is customers. ARUP realizes that the MSA
technology  has  not  yet  received FDA approval but that such approval is being
sought.  Until  FDA approval of the assay is received, ARUP intends to offer the
MSA  for  informational  purposes  to  aid  physicians  in  patient  management.

As  a  mechanism  to offer the MSA, ARUP and BMD agree as follows, ARUP's use of
the MSA will occur in two phases. During phase I, which will include the initial
launch period, ARUP will collect blood samples and send them to BMD for testing.
BMD  will produce the test results and will send a report on the testing to ARUP
within  3  business  days of BMD's receipt of the sample. ARUP will pay to BMD a
fee  for  each  test  performed  at  BMD  during  this phase, except for retests
required  because  of  inconclusive  results.  ARUP  will  send  out  technical
information  about  MSA  to  its  customers.  BMD will provide all clinical test
results  and any necessary research information to ARUP to allow ARUP to support
its  technical  disclosures  to customers. BMD will provide technical support of
the  MSA  for  ARUP  customers.

During  phase  II ARUP will take over responsibility for performing the testing.
BMD  will  supply at no charge to ARUP the necessary quality controlled reagents
and  control  materials to allow ARUP to perform testing. ARUP will pay to BMD a
royalty  for each billable test performed during the phase. BMD will sponsor and
seek  to  publish additional clinical studies to promote use of the MSA and will
also  independently promote the test service. ARUP will be mentioned as offering
the  Mammastatin test in any advertisements that BMD releases. ARUP will provide
technical  support  of the MSA for its customers during the second phase of this
relationship.

Charges  to  ARUP  for  the  testing  at  BMD  during phase I will be $95.00 per
billable  test.

The  royalty payable by ARUP to BMD for the testing at ARUP during phase II will
be  $50.00  per  billable  test.

During  phase I of this relationship BMD will invoice ARUP monthly for each test
that  is  performs  for  ARUP and will expect compensation with terms of 30 days
net.  ARUP  will  be  responsible for collecting its payment from its customers.

During  phase  II  ARUP will order the MSA reagents and materials from BMD. ARUP
will  provide  a  monthly  accounting  by the 5th business day of each month for
billable  tests  performed  in the previous month. BMD will invoice ARUP monthly
for  the  number of billable tests performed by ARUP in the previous month. ARUP
will  make  payment  with  terms  of  30  days  net.

This  Letter  of  Understanding represents the entire agreement between ARUP and
BMD.  There  is  no implied liability or contract between the parties other than
the  understanding  outlined  above.

This  agreement  can  be  terminated without cause by either party providing all
products and services are paid for under the terms of this agreement before such
termination  is  considered.

Agreed,  for

ARUP  Laboratories                       Biomedical  Diagnostics,  LLC

By:     /s/  K.  Owen  Ash     By:              /s/  James  S.  Arthurs
        ---------------------------             -----------------------------
It's:   Executive  VP,  Director  of     It's:  President
        Business  Development

<PAGE>Exhibit 10.20

                                                                    Confidential

                            NON-DISCLOSURE AGREEMENT

The  Regents  of The University of Michigan, a constitutional corporation of The
State  of  Michigan  (hereinafter  referred  to  as  "MICHIGAN")  and  Genesis
Bioventures,  Inc., with offices located at 1A 3033 King George Hwy, Surrey, BC,
Canada V4P 1B8 (hereinafter referred to as "COMPANY") each possess, and consider
to  be  proprietary  and  confidential,  certain  information,  drawings,  data,
materials,  software,  documentation,  business plans, potential licensing terms
and  know-how  relating to MICHIGAN research concerning Mammastatin diagnostics,
(all such information and materials are hereinafter referred to as "Confidential
Information").  This  agreement  has  an  effective  date of April 9, 2003.  The
relevant Confidential Information of MICHIGAN is identified in MICHIGAN's Office
of  Technology  Transfer  as  MICHIGAN  File  Nos.  1061.  It is understood that
COMPANY  and  MICHIGAN  are  both interested in having COMPANY and MICHIGAN each
receive  access  to  such  Confidential  Information  of  the other for the sole
purposes of having COMPANY participate in commercial development of Confidential
Information  and  negotiating  a license agreement regarding same.  Hereinafter,
COMPANY and MICHIGAN shall be referred to as "Party" or "Parties" as appropriate
under  the  context.

Designation  of  Information  Under  MCL  15.243  (d) and (f).   The information
provided  by  COMPANY  to  MICHIGAN  under  this  Agreement is, in its entirety,
commercial  trade-secret information voluntarily provided to MICHIGAN for use in
developing  policy  and  is  to  be  used by MICHIGAN exclusively for technology
transfer  activities  related  to  research  and evaluation.  It is submitted to
MICHIGAN  based  on  MICHIGAN's  promise  of  confidentiality, authorized by the
Office  of  the  President.

Because  such  Confidential  Information  is proprietary and confidential to the
Parties,  and  to  provide  an  appropriate  basis  by  which  such Confidential
Information  can  be  made  available  to  each  Party from the other Party, the
Parties  agree  to  the  following  terms  and  provisions.

1.     This  agreement  applies only to Confidential Information received during
the  term  of  the  May  13,  2003  License  Agreement  between  the  Parties.

2.     Except  as  provided  in  the  License  Agreement, neither Party shall be
obligated  by  this  Agreement  to  provide  to the other Party any Confidential
Information;  and  each  Party may at its sole discretion determine which of its
Confidential  Information  it  will  provide  to  the  other  Party.

3.     All  Confidential Information provided in tangible form will be marked as
such.

4.     Each Party will treat as confidential all Confidential Information, which
is or has been made available, directly or indirectly, to it by the other Party,
and  will treat it with the same degree of care that it would treat Confidential
Information  of  its  own,  and  in any event with no less than reasonable care.
From  the  date  received,  the  receiving  Party will not disclose Confidential
Information  of  the  other  Party  to  others  for  a period of five (5) years.

5.     Each  Party  will  use  Confidential  Information received from the other
Party  only  to  the  extent  necessary  for  the  aforesaid  purpose.

6.     Each  Party  agrees  to  limit  access  to  such Confidential Information
received  from  the  other  Party to those of its employees, agents, vendors and
consultants  reasonably  requiring  same  for  the aforesaid purpose and who are
obligated  to  treat  same  in  a manner and to an equivalent extent as provided
herein  with  regard  to  confidentiality,  use,  and  non-disclosure.

7.     Each  party  agrees  to  comply  with  all  applicable  laws,  rules  and
regulations,  including  Export  Administration  Regulations  and Export Control
Regulations of the United States of America, relating to the export or re-export
of  technical  data  and  products produced as a result of the use of such data,
insofar  as  they  relate  to  the  information  disclosed under this Agreement.

8.     The  secrecy  and  non-disclosure  obligations  of  each Party under this
Agreement do not apply to Confidential Information received from the other Party
which:

(a)     at  the  time  of the disclosure is generally available to the public or
thereafter  becomes generally available to the public through no act or omission
of  the  receiving  Party  or  its  employees;  or

(b)     the  receiving  Party  can  show  by written records to have been in the
receiving  Party's  possession  prior  to the time of the disclosure and was not
acquired,  directly  or  indirectly,  from  the  other  Party;  or

(c)     the  receiving  Party  can  show  by  written  records  to  have  been
independently  made  available  as  a  matter of right to the receiving Party by
others,  provided  such  others did not acquire the Confidential Information and
Material  directly  or  indirectly  from  the  other  Party;  or

(d)     is  required  to  be  disclosed  by  law  or  court  order.

<PAGE>
9.     If  the  disclosing  Party at any time requests the receiving Party to do
so,  the  receiving  Party will return all materials, drawings, data, memoranda,
and  written  information  in  its  possession  relating  to  such  Confidential
Information  of  the  disclosing  Party,  including copies thereof, to the other
Party.

10.     Nothing  contained  in this Agreement shall be construed to grant to the
receiving  Party  any  rights  in respect of such Confidential Information other
than  for  the  stated  purpose.  Nothing  herein  will obligate either Party to
proceed with any transaction between them, and each Party reserves the right, in
its sole discretion, to terminate the discussions contemplated by this Agreement
concerning  the  business  opportunity.

11.     Each Party agrees not to make any public use of or reference to the name
or trademarks (or any name under which COMPANY or MICHIGAN does business) of the
other  Party  (or  the  name  any  employee  or technology of any Party) for any
purpose  whatsoever (including marketing, public relations, advertising, display
or  other  business  purpose),  without  the  prior written consent of the other
Party,  which  consent  may be withheld or granted in the other Party's sole and
absolute  discretion.

12.     The  Parties agree that any xerographically or electronically reproduced
copy of this fully-executed agreement shall have the same legal force and effect
as  any  copy  bearing  original  signatures  of  the  parties.

13.     MICHIGAN  and  COMPANY agree that this Agreement sets forth their entire
understanding concerning confidentiality obligations, and no modification of the
Agreement  will  be  effective  unless  both MICHIGAN and COMPANY agree to it in
writing.

14.     The  parties  hereby  consent  to  the jurisdiction of the courts in the
State of Michigan over any dispute concerning this Agreement or the relationship
between  the  parties.  Should  COMPANY  bring any claim, demand or other action
against  MICHIGAN,  its Regents, fellows, officers, employees or agents, arising
out of this Agreement or the relationship between the parties, COMPANY agrees to
bring  said  action  only  in  the  Michigan  Court  of  Claims.

The  foregoing  is  understood  and  agreed  to:

                                      FOR  THE  REGENTS  OF
FOR  COMPANY                          THE  UNIVERSITY  OF  MICHIGAN

By  /s/  E.  Greg  McCartney          By  /s/  Kenneth  J.  Nisbet
    ------------------------               ------------------------
    (authorized  representative)           Kenneth  J.  Nisbet
                                           Executive Director,
                                           UM Technology Transfer

Typed  Name:  E.  Greg  McCartney
              -------------------

Title:  Chairman  /  CEO
        ----------------
Date:  May  13,  2003                 Date:  May  14,  2003
       --------------                        --------------

<PAGE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00071-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00071-of-00352.parquet"}]]